A Study of Degarelix in Taiwanese Patients With Prostate Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Prostate Cancer
Interventions
DRUG

Degarelix

Degarelix was given as subcutaneous (s.c.) injections with a 240 mg starting dose followed one month later by a 80 mg maintenance dose. The maintenance dosing was repeated for an additional 5 months (total treatment period was 168 days).

Trial Locations (10)

Unknown

Changhua Christian Hospital, Changhua

Chang Gung Medical Foundation, Chiayi Branch, Chiayi City

Chang Gung Memorial Hospital, Kaohsiung, Kaohsiung City

Kaohsiung Veterans General Hospital, Kaohsiung City

China Medical University Hospital, Taichung

Taichung Veterans General Hospital, Taichung

Chi-Mei Foundation Hospital, Tainan City

National Taiwan University Hospital, Taipei

Taipei Veterans General Hospital, Taipei

Chang Gung Memorial Hospital, Linkuo, Taoyuan District

Sponsors
All Listed Sponsors
lead

Ferring Pharmaceuticals

INDUSTRY